A View on Prevention of Cervical Cancer by Human Papillomavirus Vaccination

Cervical cancer, the fourth leading cause of death in women is mainly caused by sexually transmitted Human Papillomavirus (HPV). HPV consists of over 200 serotypes, out of which 12 types of HPV are considered high-risk, especially type 16 and 18 being the most oncogenic types. To prevent the incidence and prevalence of cervical cancer, administration of HPV vaccination is recommended. There are 3 types of vaccines approved by FDA, namely Bivalent, Quadrivalent, and Nonavalent HPV vaccines consisting of 0.5ml in each dose scheduled to 2 doses for children between 9 to 14 years, and humans above 15 years are recommended with 3 doses with few months apart. Although the vaccine is beneficial, it is noted that many were unable to get it due to various barriers in which the cost of the vaccine plays a key role, and lack of awareness on both disease, vaccine, and dose schedules plays another role. In order to make the vaccine available for everyone worldwide, single-dose administration is taken into consideration